Health Care • Medical/Dental Instruments
$119.65 ▼ -0.14
(-0.12%)
MKT CAP: $5.44B • VOL: 453.4K
52W L $50 52W H $124
HAE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-28 | FY 2024
FILED 2025-03-29 | FY 2023
FILED 2024-03-30 |
|---|---|---|---|
| Revenue (Total Sales) | $1.33B | $1.36B | $1.31B |
| YoY Revenue Growth % | -2.0% | +4.0% | — |
| Gross Profit | $787.6M | $749.0M | — |
| Gross Margin % | 59.0% | 55.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $156.7M | $221.8M | $164.9M |
| Operating Margin % | 11.7% | 16.3% | 12.6% |
| Net Income (GAAP) | $97.3K | $167.7K | $117.6M |
| EBITDA (Normalized) | $183.0M | $253.2M | $212.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $293.2M | $181.7M | $181.8M |
| Capital Expenditures (CapEx) | $32.8M | $39.3M | $58.9M |
| Free Cash Flow (FCF) | $260.4M | $142.4M | $122.8M |
| FCF Margin % | 19.5% | 10.5% | 9.4% |
| Return on Invested Capital (ROIC %) | 8.4% | 9.7% | 7.2% |
| Cash & Short-Term Equivalents | $363.4M | $320.8M | — |
| Total Debt (Short + Long Term) | $920.0M | $1.22B | $701.4M |
| Total Stockholders' Equity | $911.5M | $906.9M | $1.44B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HAE.